hidradenitis suppurativa and glp 1 GLP-1s Linked to Systemic Clinical Risk Reduction in GLP-1 RAs Show Benefits for
Description
The drug has been approved for prescription to UK adults with a body mass index of 30 or above, or who are overweight with a BMI between 27 and 30 and at least one weight-related condition
Patients who will not inject often end up on orforglipron
Pushing to 12mg for an additional three percentage points is not always worth the trade-off
Patients who prioritize a balanced lifestyle often experience better and faster outcomes
271 (2), R848R856
